UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
September 20, 2005
------------------------------------------------
Date of Report (Date of earliest event reported)
GENOMED, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Florida 000-49720 43-1916702
- ---------------------------- ------------------ ----------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
9666 OLIVE BOULEVARD, SUITE 310, ST. LOUIS, MISSOURI 63131
----------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(314) 983-9933
----------------------------------------------------
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
SECTION 4- MATTER RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS
ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING AUDITORS
Effective September 20, 2005, the Registrant's auditors Stark Winter
Schenkein & Co., LLP ("Stark") resigned.
During the period of engagement from May 3, 2005, through September 20,
2005, there were no disagreements between the Registrant and Stark on any matter
of accounting principles or practices, financial statement disclosure or
auditing scope or procedure which, if not resolved to the satisfaction of Stark
would have caused Stark to make reference to the matter in its reports on the
Registrant's financial statements, had any such reports been issued. During the
period of engagement from May 3, 2005, through September 20, 2005, there were no
reportable events as the term described in Item 304(a)(1)(iv) of Regulation S-B.
At this time, the Registrant has not yet engaged a new certifying
auditors. Discussions with potential new auditors are underway at present.
The Registrant has provided to Stark Winter a copy of the disclosures
in this report and the Registrant has requested a letter from Stark Winter
addressed to the Commission confirming the statements made by the Registrant in
this report. A copy of that letter is attached as an exhibit to this report.
SECTION 9- FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 EXHIBITS
16.1 Letter from Stark Winter Schenkein & Co. LLP
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GenoMed, Inc.
Dated: November 18, 2005. By: /s/ DAVID MOSKOWITZ MD, MA (Oxon.),FACP
Chairman,
Chief Executive Officer, and
Chief Medical Officer